17 November 2026Research and development in Australia
Australian R&D
Founder profile

Laronix: from a research project to a voice box people can sing with

Brisbane medtech Laronix turned academic research into AVA, an artificial larynx now on sale in Australia. Its CEO on how the R&D was paid for.

By Australian R&D staff · 4 November 2026 · 2 min read

Laronix is a Brisbane medical technology company that makes artificial voice boxes for people who have lost their voice. Its first product, AVA, is an artificial larynx that its chief executive says lets people sing and laugh, and it is now on sale to patients in Australia (Laronix).

From lab to clinic

The company “started as a research project funded by academic institutions” and has operated since 2020, according to its website (Laronix). It was co-founded by Dr Farzaneh (Fary) Ahmadi, its chief executive, and Dr Mousa Ahmadi, its chief operating officer. It describes itself as an ISO 13485 certified medical device manufacturer, and has offices in Brisbane and White Plains, New York.

The government's case study says the devices are non-invasive and use software and AI “to produce a sound that mimics the voice of the wearer”. A second product, MIRA, is a handheld electronic device. The company's site cites “over 18 months of successful clinical adoption” for AVA.

How the R&D was paid for

Ahmadi was direct about the money in a business.gov.au video. “We’ve used the R&D Tax Incentive proceeds to design and develop AVA, which is now commercialized. And now we are focused on designing and developing Mira.” (business.gov.au)

She explained why companies hesitate: “Because R&D is a resource exhaustive process and there is uncertainty in it, companies are hesitant to step into that front.” And she compared Australia with other markets: “We work with other countries as well, and we haven’t seen a government this supportive with this special scheme to support innovation anywhere in the world.”

“A country is always as good as its plans around innovation because that’s essentially what defines the future.”

Dr Farzaneh Ahmadi, CEO, Laronix

Why it matters

Medical devices take years and regulatory approval before they earn money, which is why medtech groups pushed back on the 2028 plan to limit refunds to companies under 10 years old. The bill introduced to Parliament in late October extends refunds to 15 years for biotech and medtech firms. See our analysis of the changes.

Based on Laronix's website and a business.gov.au case study, which the government publishes to promote the program.

More founders